|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
RATE OF CHANGE
Trading: BUY @ $1.805
Signal Strength: MEDIUM
Mesoblast (ASX:MSB) currently has positive rate of change of 1.977%. This means the current price is greater than the price 14 days ago and therefore gaining momentum.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Rate of Change (ROC) is a refinement of Momentum - readings fluctuate as percentages around the zero line. The indicator is designed for use in ranging markets - to detect trend weakness and likely reversal points. However when combined with a trend indicator it can be used in trending markets.
Calculation: Rate of Change (ROC):
1) (Closing Price [today] - Closing Price [n days ago]) / Closing Price [n days ago] * 100
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|EML Emerchants||4.35||13.6||7,106,370||9.3||BULLISH CROSSOVER|
|CGS Cogstate||0.36||12.5||54,332||4.35||BULLISH CROSSOVER|
|APX Appen||22.66||5.9||1,026,466||5.54||BULLISH CROSSOVER|
|SMN Structural Monitoring Systems||0.98||4.8||47,285||3.16||BULLISH CROSSOVER|
|PGC Paragon Care||0.43||3.6||423,426||4.88||BULLISH CROSSOVER|
|SMX Sms Management & Technology||0.3||3.4||1,266||3.45||BULLISH CROSSOVER|
|DNK Danakali||0.65||3.2||124,521||3.18||BULLISH CROSSOVER|
|MTO Moto Goldmines||2.39||3||16,084||1.7||BULLISH CROSSOVER|
|BBN Baby Bunting||3.81||3||429,199||2.42||BULLISH CROSSOVER|
|MVF Monash IVF||1.03||2.5||1,948,555||1.48||BULLISH CROSSOVER|